EUVIMEDEUVIMED entdecken
Crossref

Natural Product Daidzin Inhibits Glioma Development via Suppressing the LRP5 ‐Mediated GSK ‐3 β /c‐Myc Signaling Pathway

Yijing Pan, Shunshun Wang, Guoliang Duan, Jiaqin Wu, Fan Feng, Lin Chen, Anzheng Li, Kang Xu iD, Chunli Wang iD, Shibing Fan

BioFactors · 2025-05 · 51 (3)

DOI: 10.1002/biof.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, online erschienen am 06.06.2025. Verfasst von Yijing Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Provincial Engineering Technology Research Center for Chinese Medicine Processing, School of Pharmacy, Hubei University of Chinese Medicine, Wu…. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Proto-Oncogene Proteins c-myc, Low Density Lipoprotein Receptor-Related Protein-5, Glioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Chongqing Wanzhou Science and Technology Plan Project, Academy-level scientific research projects of Chongqing University Three Gorges Hospital, Chongqing Natural Science Foundation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daidzin (DZN) is a natural flavonoid compound derived from soybeans that has recently been recognized for its potential antitumor properties. In traditional Chinese medicine, soybeans and their extracts are extensively used to prevent and treat various diseases. To evaluate the therapeutic efficacy of DZN on human glioblastoma through in vivo and in vitro experiments, and through multi‐omics analyses to elucidate potential molecular mechanisms. Cell viability of LN‐229 and U‐87MG glioblastoma cells was assessed using the CCK‐8 assay. Protein and mRNA levels of proliferation and apoptosis‐related genes were analyzed via Western blotting and qPCR. Metabolomics and transcriptomics identified key pathways and targets, which were confirmed by in‐cell Western blotting and expression correlation analysis. The in vivo antitumor effects of DZN were evaluated in nude mice with LN‐229 tumors. DZN treatment reduced cell viability, migration, and survival in a dose‐dependent manner, demonstrating strong antitumor effects in both in vitro and in vivo models. Multi‐omics analysis identified amino acid metabolism and ubiquitin‐mediated proteolysis as key mechanisms. Bioinformatics highlighted LRP5 as a prognostic biomarker in glioblastoma. DZN decreased LRP5 activity, downregulated p‐GSK‐3 β , and promoted c‐Myc degradation, thereby inhibiting the Wnt signaling pathway. In vivo, DZN significantly reduced tumor size and Ki67 expression. These findings highlight LRP5 as a promising therapeutic target, with DZN emerging as a potent LRP5 inhibitor and exhibiting significant antitumor effects in glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-mycLow Density Lipoprotein Receptor-Related Protein-5GliomaIsoflavonesGlioblastomaBrain NeoplasmsHumansAnimalsMiceCell Line, TumorCell ProliferationMice, NudeSignal TransductionXenograft Model Antitumor AssaysApoptosisGene Expression Regulation, NeoplasticCell SurvivalCell Movement

Stichwörter der Autor:innen

LRP5antitumor effectsc‐Myc phosphorylationgliomasubiquitin‐dependent proteolysis

Substanzen

Glycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-mycLow Density Lipoprotein Receptor-Related Protein-5MYC protein, humanIsoflavonesGSK3B protein, human

Autor:innen und Institutionen

  • Hubei Provincial Engineering Technology Research Center for Chinese Medicine Processing, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
  • Chongqing University Three Gorges Hospital, and School of Medicine Chongqing University, Chongqing, People's Republic of China.
  • Hubei Shizhen Laboratory, Wuhan, China.
  • School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan, China.
  • Department of Pediatric Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Kang Xu, Chunli Wang

Förderung

  • Chongqing Wanzhou Science and Technology Plan Project
  • Academy-level scientific research projects of Chongqing University Three Gorges Hospital
  • Chongqing Natural Science Foundation Project
  • Chongqing Science and Health Joint Medical Research Project

Zitieren

APA

Pan, Y., Wang, S., Duan, G., Wu, J., Feng, F., Chen, L., Li, A., Xu, K., Wang, C., & Fan, S. (2025). Natural Product Daidzin Inhibits Glioma Development via Suppressing the LRP5 ‐Mediated GSK ‐3 β /c‐Myc Signaling Pathway. BioFactors, 51(3). https://doi.org/10.1002/biof.70025

Vancouver

Pan Y, Wang S, Duan G, Wu J, Feng F, Chen L, et al. Natural Product Daidzin Inhibits Glioma Development via Suppressing the LRP5 ‐Mediated GSK ‐3 β /c‐Myc Signaling Pathway. BioFactors. 2025;51(3). doi:10.1002/biof.70025

BibTeX
@article{Pan2025,
  author = {Pan, Yijing and Wang, Shunshun and Duan, Guoliang and Wu, Jiaqin and Feng, Fan and Chen, Lin and Li, Anzheng and Xu, Kang and Wang, Chunli and Fan, Shibing},
  title = {Natural Product Daidzin Inhibits Glioma Development via Suppressing the LRP5 ‐Mediated GSK ‐3 β /c‐Myc Signaling Pathway},
  journal = {BioFactors},
  year = {2025},
  volume = {51},
  number = {3},
  doi = {10.1002/biof.70025}
}
Kostenlos starten →